|
WO2020093011A1
|
|
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
TW202035365A
|
|
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2019143730A1
|
|
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
AU2019209470A1
|
|
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
BR112020007204A2
|
|
pyrrolotriazine compounds and methods of inhibiting tam kinases
|
|
US2020291018A1
|
|
Tam kinase inhibitors
|
|
AU2018282901A1
|
|
Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
WO2018191587A1
|
|
Tam kinase inhibitors
|
|
WO2018187357A1
|
|
Compositions of cyclin-dependent kinase 7 (cdk7) inhibitor
|
|
WO2018136961A1
|
|
METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
|
|
TW201823471A
|
|
Methods of treating patients with a retinoic acid receptor-[alpha] agonist and an anti-CD38 antibody
|
|
US2019048019A1
|
|
Compounds for the modulation of myc activity
|
|
KR20190038841A
|
|
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US2017292165A1
|
|
Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
|
|
AU2017248187A1
|
|
Rara agonists for the treatment of AML and MDS
|
|
US2018162851A1
|
|
Compounds for the modulation of myc activity
|
|
WO2016196910A1
|
|
Compounds for the modulation of myc activity
|
|
KR20170132248A
|
|
Methods for stratifying patients for treatment with retinoic acid receptor-a agonists
|
|
AU2016211186A1
|
|
High surface-area lyophilized compositions comprising arsenic for oral administration in patients
|
|
US2017327496A1
|
|
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
